NASDAQ:MORF - Morphic Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $43.50
  • Forecasted Upside: -41.92 %
  • Number of Analysts: 3
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 3 Buy Ratings
  • 0 Strong Buy Ratings
$74.90
▲ +38.74 (107.13%)
1 month | 3 months | 12 months
Get New Morphic Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for MORF and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for MORF

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$43.50
▼ -41.92% Downside Potential
This price target is based on 3 analysts offering 12 month price targets for Morphic in the last 3 months. The average price target is $43.50, with a high forecast of $50.00 and a low forecast of $37.00. The average price target represents a -41.92% upside from the last price of $74.90.
Buy
The current consensus among 3 polled investment analysts is to buy stock in Morphic.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/8/2019
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/7/2019
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/6/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/4/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/2/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/1/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/30/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/1/2021

Latest Recommendations

  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
2/2/2021Royal Bank of CanadaBoost Price TargetOutperform$35.00 ➝ $50.00Low
i
10/26/2020Royal Bank of CanadaInitiated CoverageOutperform$35.00High
i
8/26/2020BMO Capital MarketsReiterated RatingBuy$37.00Medium
i
8/11/2020BMO Capital MarketsBoost Price TargetOutperform$30.00 ➝ $37.00Low
i
7/5/2020BMO Capital MarketsReiterated RatingBuyLow
i
3/5/2020CowenReiterated RatingBuyLow
i
8/13/2019BMO Capital MarketsBoost Price TargetOutperform$30.00 ➝ $32.00High
i
8/12/2019CowenReiterated RatingBuyHigh
i
7/22/2019Jefferies Financial GroupInitiated CoverageBuy ➝ BuyHigh
i
7/22/2019CowenInitiated CoverageOutperform ➝ OutperformHigh
i
7/22/2019Wells Fargo & CompanyInitiated CoverageOutperform ➝ OutperformHigh
i
7/22/2019BMO Capital MarketsInitiated CoverageOutperform ➝ Outperform$30.00High
i
(Data available from 3/1/2016 forward)
Morphic logo
Morphic Holding, Inc., a biopharmaceutical company, discovers and develops oral small-molecule integrin therapeutics for the treatment of autoimmune, cardiovascular, and metabolic diseases, as well as fibrosis and cancer. Its lead product candidates in clinical development are MORF-720, a selective oral avÃ6 specific integrin inhibitor for the treatment of idiopathic pulmonary fibrosis (IPF) and primary sclerosing cholangitis (PSC); and MORF-057, a a4Ã7 specific integrin inhibitor for the treatment of inflammatory bowel disease (IBD). The company is also developing MR Ã6 #2, a selective avÃ6 specific integrin inhibitor to treat IPF and PSC; and avÃ1 integrin for the treatment of fibrosis. Morphic Holding, Inc. has a research collaboration with Engitix Ltd for the identification of Morphic integrin technology amenable targets in fibrostenotic IBD; a collaboration agreement with Schrödinger, LLC for integrin targets; and a license agreement with Children's Medical Center Corporation to develop and commercialize products worldwide for any therapeutic or diagnostic use in humans and veterinary applications. It also has collaboration agreements with AbbVie Biotechnology Ltd and Janssen Pharmaceuticals, Inc. to discover or develop integrin-based therapeutics; and drug discovery research collaboration with HitGen Inc. to identify small molecule leads against targets specified by the company. The company was founded in 2014 and is based in Waltham, Massachusetts.
Read More

Today's Range

Now: $74.90
$42.40
$78.48

50 Day Range

MA: $33.96
$29.77
$39.93

52 Week Range

Now: $74.90
$9.90
$42.00

Volume

115,281 shs

Average Volume

136,337 shs

Market Capitalization

$2.33 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.01

Frequently Asked Questions

What sell-side analysts currently cover shares of Morphic?

The following equities research analysts have issued research reports on Morphic in the last twelve months: BMO Capital Markets, Cowen Inc, Royal Bank of Canada, and Zacks Investment Research.
View the latest analyst ratings for MORF.

What is the current price target for Morphic?

2 Wall Street analysts have set twelve-month price targets for Morphic in the last year. Their average twelve-month price target is $43.50, suggesting a possible downside of 41.3%. Royal Bank of Canada has the highest price target set, predicting MORF will reach $50.00 in the next twelve months. BMO Capital Markets has the lowest price target set, forecasting a price of $37.00 for Morphic in the next year.
View the latest price targets for MORF.

What is the current consensus analyst rating for Morphic?

Morphic currently has 3 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe MORF will outperform the market and that investors should add to their positions of Morphic.
View the latest ratings for MORF.

What other companies compete with Morphic?

How do I contact Morphic's investor relations team?

Morphic's physical mailing address is 35 Gatehouse Drive A2, Waltham MA, 02451. The company's listed phone number is 781-996-0955. The official website for Morphic is www.morphictx.com.